EUVIMEDEUVIMED entdecken
Crossref

Resource utilization and costs of managing severe adverse events associated with chemotherapy and immunotherapy in lung cancer: a consensus-based microcosting study in Jordan

Saba Madae'en, Ahmed Salem, Naila Ararawi, Ezzaldeen Ramzi, Abdallah Alhunity, Hani El Taani, Taher Abu Hejleh, Osama Abu Hlalah, Sameer Yaser, Mostafa Qasem

Expert Review of Pharmacoeconomics & Outcomes Research · 01.11.2026 · 1-10

DOI: 10.1080/14737167.2026.2755201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 01.11.2026. Verfasst von Saba Madae'en und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa, Jordan. Die Arbeit nennt 58 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: To estimate the direct medical costs of managing panel‑selected Grade III/IV adverse events that were considered most relevant to the Jordanian clinical setting associated with chemo-immunotherapy regimens in lung cancer patients from the Jordanian healthcare provider perspective and to identify the principal cost drivers. METHODS: A microcosting approach was employed, utilizing consensus-based management protocols derived through a two-round modified Delphi process in Jordan. Fourteen Grade III/IV adverse events were evaluated. Episode costs were estimated from adverse-event detection to acute clinical resolution in 6 months where applicable or 6 months of treatment for chronic adverse events, using multiple Jordanian cost sources. One-way deterministic sensitivity analysis was performed. No discount rate was applied due to the costing of one episode less than a year duration. RESULTS: Base-case episode costs ranged from $55.06 for maculopapular rash to $5118.17 for pneumonitis. The five most costly adverse events per episode were pneumonitis ($5118.17), myocarditis ($3872.05), diarrhea and colitis ($3008.23), febrile neutropenia ($2,876.81), and thrombocytopenia ($2867.94). Hospitalization was the dominant cost driver, accounting for 47.4% of mean episode costs across all adverse events. CONCLUSION: These consensus-derived unit cost estimates provide critical inputs for future cost-effectiveness analyses of lung cancer systemic therapies in Jordan.

Schlagwörter

Stichwörter der Autor:innen

Adverse eventschemotherapycost analysisimmunotherapymicrocostingresource utilization

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa, Jordan.
  • Department of Anatomy, Physiology and Biochemistry, Faculty of Medicine, The Hashemite University, Zarqa, Jordan.
  • Faculty of Medicine, Hashemite University, Zarqa, Jordan.
  • Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, King Abdullah University Hospital, Jordan University of Science and Technology, Irbid, Jordan.
  • Oncology and Hematology Department, Abdali Hospital, Amman, Jordan.
  • Division of Hematology, Oncology, Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

Zitieren

APA

Madae'en, S., Salem, A., Ararawi, N., Ramzi, E., Alhunity, A., El Taani, H., Abu Hejleh, T., Abu Hlalah, O., Yaser, S., & Qasem, M. (2026). Resource utilization and costs of managing severe adverse events associated with chemotherapy and immunotherapy in lung cancer: a consensus-based microcosting study in Jordan. Expert Review of Pharmacoeconomics & Outcomes Research, 1-10. https://doi.org/10.1080/14737167.2026.2755201

Vancouver

Madae'en S, Salem A, Ararawi N, Ramzi E, Alhunity A, El Taani H, et al. Resource utilization and costs of managing severe adverse events associated with chemotherapy and immunotherapy in lung cancer: a consensus-based microcosting study in Jordan. Expert Review of Pharmacoeconomics & Outcomes Research. 2026:1-10. doi:10.1080/14737167.2026.2755201

BibTeX
@article{Madaeen2026,
  author = {Madae'en, Saba and Salem, Ahmed and Ararawi, Naila and Ramzi, Ezzaldeen and Alhunity, Abdallah and El Taani, Hani and Abu Hejleh, Taher and Abu Hlalah, Osama and Yaser, Sameer and Qasem, Mostafa},
  title = {Resource utilization and costs of managing severe adverse events associated with chemotherapy and immunotherapy in lung cancer: a consensus-based microcosting study in Jordan},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2026},
  pages = {1--10},
  doi = {10.1080/14737167.2026.2755201}
}
Kostenlos starten →